Anti-Osteoprotegerin 抗体 [bony-1] (ab18051)


  • 製品名Anti-Osteoprotegerin antibody [bony-1]
    Osteoprotegerin 一次抗体 製品一覧
  • 製品の詳細
    Rat monoclonal [bony-1] to Osteoprotegerin
  • 特異性Recognizes human OPG
  • アプリケーション適用あり: Flow Cyt, IPmore details
  • 種交差性
    交差種: Human
  • 免疫原

    Recombinant fragment, corresponding to amino acids 22-202 of Human Osteoprotegerin.



Our Abpromise guarantee covers the use of ab18051 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
Flow Cyt 1/1000. ab18450-Rat monoclonal IgG2a, is suitable for use as an isotype control with this antibody.
IP 1/200.


  • 機能Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis.
  • 組織特異性Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung.
  • 関連疾患Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD) [MIM:239000]; also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast-mediated skeletal resorption, the disease can be fatal.
  • 配列類似性Contains 2 death domains.
    Contains 4 TNFR-Cys repeats.
  • 翻訳後修飾N-glycosylated. Contains sialic acid residues.
    The N-terminus is blocked.
  • 細胞内局在Secreted.
  • Information by UniProt
  • 参照データベース
  • 別名
    • MGC29565 antibody
    • OCIF antibody
    • OPG antibody
    • Osteoclastogenesis inhibitory factor antibody
    • Osteoprotegerin antibody
    • PDB5 antibody
    • TNF receptor superfamily member 11b antibody
    • TNFRSF 11B antibody
    • TNFRSF11B antibody
    • TR 1 antibody
    • TR1 antibody
    • TR11B_HUMAN antibody
    • Tumor necrosis factor receptor superfamily member 11B antibody
    see all

Anti-Osteoprotegerin antibody [bony-1] 画像

  • FACS analysis of cells with ab18051.
    HEK 293T cells (5 x 105) were mock transfected (thin line) or transfected with an expression plasmid enabling surface expression of the TNFR homology domain of human OPG (thick line). Cells were incubated on ice for 30 min in 50µl FACS buffer (PBS, 5% fetal calf serum, 0.02% azide)
    containing 1µg/ml of ab18051. After washing in FACS buffer, R-PE-conjugated antibody to rat IgG was added. Cells were incubated on ice for 30 min, washed and then analyzed by Flow Cytometry.

Anti-Osteoprotegerin antibody [bony-1] (ab18051) 使用論文

ab18051 has not yet been referenced specifically in any publications.

Product Wall

Thank you for contacting us. Unfortunately both anti-Osteoprotegerin antibody ab18051 and ab9986 have not as yet been assessed for their neutralising activity to our knowledge. This does not mean that these will not work as a neutralising antibodie...

Read More